Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.

Majed Ramadan, Rwiah Alsiary, Noor Alsaadoun, Noara Alhusseini, Muhammad Raihan Sajid, Noor Mohamed Hamed, Tarek Ziad Arabi, Belal Nedal Sabbah
{"title":"Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.","authors":"Majed Ramadan,&nbsp;Rwiah Alsiary,&nbsp;Noor Alsaadoun,&nbsp;Noara Alhusseini,&nbsp;Muhammad Raihan Sajid,&nbsp;Noor Mohamed Hamed,&nbsp;Tarek Ziad Arabi,&nbsp;Belal Nedal Sabbah","doi":"10.1177/11782234231158270","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The risk of breast cancer progression is one of the most difficult factors to predict as it is studied in different populations, patient groups, or time frames, resulting in conflicting estimates of incidence rates reported in the literature. The purpose of this study is to identify predictive factors for breast cancer recurrences in a sample of the Middle Eastern population.</p><p><strong>Methodology: </strong>A cohort retrospective study included all eligible breast cancer patients at the National Guard Health Affairs (NGHA) Hospital in Jeddah, Western region, from 2015 to 2021. Our primary outcome was the progression status of the patients; we adjusted for demographic, clinical, and molecule characteristics of the population. From 2015 to 2021, there were 319 patients diagnosed with breast cancer. Multiple logistic regression analysis was used to estimate predictors of breast cancer progression.</p><p><strong>Results: </strong>One of five breast cancer patients had breast cancer progression (20.83%), while 66.15% of the progression patients were between the ages of 41-65. In multivariate analysis, age, progesterone receptor (PR), family history, and tumor size were significant predictors of breast cancer progression. The age group of 20-40 years was a protective predictor of breast cancer progression, patients in the young age group were less likely to be diagnosed with progression (OR = 0.35; CI = 0.15, 0.81). While negative PRs and tumor size greater than 2 cm were significant predictor factors of breast cancer progression (OR = 2.07; CI = 1.09, 3.91, OR = 2.02; CI = 1.9, 3.78).</p><p><strong>Conclusion: </strong>Although the effect of young age as a protective factor for the progression of breast cancer remains controversial, our study revealed that patients between 41 and 60 years of age had a higher rate of progression. Future larger prospective studies are needed to delineate the role of age and PR hormone receptors in determining the best treatment options for women with breast cancer in the Saudi population.</p>","PeriodicalId":9163,"journal":{"name":"Breast Cancer : Basic and Clinical Research","volume":"17 ","pages":"11782234231158270"},"PeriodicalIF":1.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/af/10.1177_11782234231158270.PMC10061810.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Basic and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11782234231158270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The risk of breast cancer progression is one of the most difficult factors to predict as it is studied in different populations, patient groups, or time frames, resulting in conflicting estimates of incidence rates reported in the literature. The purpose of this study is to identify predictive factors for breast cancer recurrences in a sample of the Middle Eastern population.

Methodology: A cohort retrospective study included all eligible breast cancer patients at the National Guard Health Affairs (NGHA) Hospital in Jeddah, Western region, from 2015 to 2021. Our primary outcome was the progression status of the patients; we adjusted for demographic, clinical, and molecule characteristics of the population. From 2015 to 2021, there were 319 patients diagnosed with breast cancer. Multiple logistic regression analysis was used to estimate predictors of breast cancer progression.

Results: One of five breast cancer patients had breast cancer progression (20.83%), while 66.15% of the progression patients were between the ages of 41-65. In multivariate analysis, age, progesterone receptor (PR), family history, and tumor size were significant predictors of breast cancer progression. The age group of 20-40 years was a protective predictor of breast cancer progression, patients in the young age group were less likely to be diagnosed with progression (OR = 0.35; CI = 0.15, 0.81). While negative PRs and tumor size greater than 2 cm were significant predictor factors of breast cancer progression (OR = 2.07; CI = 1.09, 3.91, OR = 2.02; CI = 1.9, 3.78).

Conclusion: Although the effect of young age as a protective factor for the progression of breast cancer remains controversial, our study revealed that patients between 41 and 60 years of age had a higher rate of progression. Future larger prospective studies are needed to delineate the role of age and PR hormone receptors in determining the best treatment options for women with breast cancer in the Saudi population.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
沙特阿拉伯西部地区乳腺癌治疗后进展的风险
背景:乳腺癌进展的风险是最难预测的因素之一,因为它是在不同的人群、患者群体或时间框架中研究的,导致文献中报道的发病率估计相互矛盾。本研究的目的是确定中东人群中乳腺癌复发的预测因素。方法:队列回顾性研究纳入2015年至2021年西部吉达国民警卫队卫生事务(NGHA)医院所有符合条件的乳腺癌患者。我们的主要结局是患者的进展状态;我们根据人口统计学、临床和分子特征进行了调整。从2015年到2021年,有319名患者被诊断为乳腺癌。采用多元logistic回归分析来估计乳腺癌进展的预测因子。结果:每5例乳腺癌患者中就有1例发生乳腺癌进展(20.83%),66.15%的进展患者年龄在41-65岁之间。在多变量分析中,年龄、孕激素受体(PR)、家族史和肿瘤大小是乳腺癌进展的重要预测因素。20-40岁年龄组是乳腺癌进展的保护性预测因子,年轻年龄组的患者被诊断为进展的可能性较小(OR = 0.35;Ci = 0.15, 0.81)。而pr阴性和肿瘤大小大于2 cm是乳腺癌进展的显著预测因素(OR = 2.07;Ci = 1.09, 3.91, or = 2.02;Ci = 1.9, 3.78)。结论:尽管年轻作为乳腺癌进展的保护因素的作用仍存在争议,但我们的研究显示,41至60岁的患者有更高的进展率。未来需要更大规模的前瞻性研究来描述年龄和PR激素受体在确定沙特女性乳腺癌最佳治疗方案中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.10
自引率
3.40%
发文量
22
审稿时长
8 weeks
期刊介绍: Breast Cancer: Basic and Clinical Research is an international, open access, peer-reviewed, journal which considers manuscripts on all areas of breast cancer research and treatment. We welcome original research, short notes, case studies and review articles related to breast cancer-related research. Specific areas of interest include, but are not limited to, breast cancer sub types, pathobiology, metastasis, genetics and epigenetics, mammary gland biology, breast cancer models, prevention, detection, therapy and clinical interventions, and epidemiology and population genetics.
期刊最新文献
Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study. ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases. Quality of Life in Female Breast Cancer Patients and Survivors in a South African Municipality. Serum and Fecal Metabolite Profiles Linking With Gut Microbiome in Triple-Negative Breast Cancer Patients. Higher 10-Year Survival with Breast-Conserving Therapy over Mastectomy for Women with Early-Stage (I-II) Breast Cancer: Analysis of the CDC Patterns of Care Data Base.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1